secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atea Pharmaceuticals, Inc. (AVIR)
CIK:        0001593899
Form:       8-K
Filed at:   2025-01-14T23:59:59+00:00
Accession:  0001193125-25-005424
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atea reports $454.7M cash, plans global Phase 3 HCV program starting Q1 2025
----------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities $454.7M at Dec 31, 2024; cash runway into 2028.
- Phase 2 study met primary endpoints: 98% SVR12 in per-protocol population, 95% in efficacy evaluable (n=256).
- Global Phase 3 program for bemnifosbuvir + ruzasvir expected to initiate in Q1 2025; two open-label trials.
- End-of-Phase 2 meeting with FDA scheduled January 2025 to discuss Phase 3 program design.
- Company estimates global HCV market ~$3B annual net sales; regimen has potential best-in-class profile.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1593899/000119312525005424/0001193125-25-005424-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1593899/000119312525005424/d924755d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-005424

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer